Treatment of Clinically Diagnosed Alzheimer's Disease by External Counterpulsation A Randomized Clinical Trial - PubMed
3 days ago
- #Alzheimer's disease
- #cognitive function
- #external counterpulsation
- External counterpulsation (ECP) was tested in a 12-month randomized, sham-controlled trial for early Alzheimer's disease.
- ECP significantly improved activities of daily living (ADCS-ADL) and cognitive function (VADAS-cog) compared to sham at 12-24 weeks.
- Benefits persisted for up to 52 weeks, even though treatment stopped at 6 months.
- The therapy involved 35 one-hour sessions, initially frequent then reduced, with no serious device-related adverse events.
- The study suggests ECP as a promising novel therapeutic approach for early AD, warranting further investigation.